Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines
| Autor: | Nai-Xiong Peng, Chun-Xiao Liu, Xi-Sheng Wang, Ze-Jian Zhang, Su-Cai Liao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Bangladesh Journal of Pharmacology, Vol 11, Iss 1 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1991-0088 17444187 |
| DOI: | 10.3329/bjp.v11i1.24149 |
| Popis: | Prostate cancer is the major cause of cancer-related deaths worldwide in men. There are new treatment methods and drugs are being developed with promising results in two of the prostate cancer cell lines (PPC-1 and TSU-Pr1). These two cells were treated with 20 uM of axitinib combined with dasatinib for 6-72 hours. The cell viability assessed by the cytotoxicity assay. Various regulatory genes such as c-KIT, cell cycle and apoptosis and angiogenic factors were also studied. The enzyme activity of apoptosis effector caspase-3 was colorimetrically determined. Axitinib and dasatinib combination lowered the survival rate of PPC-1 cells but enhanced the survival rate of TSU-Pr1 cells. The protein expression levels in apoptosis and angiogenesis factors were also found to be in contrast between the two cell lines. PPC-1 and TSU-Pr1 cells displayed a different response to axitinib with dasatinib, which explains different expression levels of regulators of cell-cycle, apoptosis and angiogenesis. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|